Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 0.5% – Time to Sell?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT)’s stock price was down 0.5% during trading on Monday . The company traded as low as $1.8522 and last traded at $1.93. Approximately 14,434 shares were traded during mid-day trading, a decline of 9% from the average daily volume of 15,792 shares. The stock had previously closed at $1.94.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Alaunos Therapeutics has an average rating of “Sell”.

Alaunos Therapeutics Price Performance

The stock has a fifty day moving average of $2.23 and a two-hundred day moving average of $2.65. The stock has a market cap of $46.40 million, a price-to-earnings ratio of -0.89 and a beta of -1.02.

Alaunos Therapeutics (NASDAQ:TCRT) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.59) EPS for the quarter.

Institutional Trading of Alaunos Therapeutics

A hedge fund recently raised its stake in Alaunos Therapeutics stock. Geode Capital Management LLC raised its holdings in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) by 25.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,736 shares of the company’s stock after buying an additional 3,945 shares during the period. Geode Capital Management LLC owned about 0.85% of Alaunos Therapeutics worth $64,000 at the end of the most recent reporting period. 27.72% of the stock is owned by hedge funds and other institutional investors.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.